Setting

Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity

Published: 30 Jun 2021 | Report Code: 10248050 | Pages: 86

Europe amyotrophic lateral sclerosis treatment market accounted for $129.5 million in 2020 and will grow by 5.4% annually over 2020-2027 owing to the rising geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies. Highlighted with 31 tables and 35 figures, this 86-page report “Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Europe amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Country. Based on Treatment Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Medication o Riluzole (Rilutek) o Radicava (Edaravone) o Tiglutik (Thickened Riluzole) o Nuedexta • Stem Cell Therapy • Other Treatments Based on ALS Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Sporadic ALS • Familial ALS Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Other Distribution Channels Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AB Science SA Amylyx Pharmaceuticals Inc. Biogen Inc. Biohaven Pharmaceutical Holding Co., Ltd. BrainStorm Cell Limited Corestem, Inc. F.Hoffmann-La Roche AG Ionis Pharmaceuticals, Inc. Mitsubishi Tanabe Pharma Corporation Otsuka Pharmaceutical Co., Ltd. Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	6
1.1 Industry Definition and Research Scope	6
1.1.1 Industry Definition	6
1.1.2 Research Scope	7
1.2 Research Methodology	10
1.2.1 Overview of Market Research Methodology	10
1.2.2 Market Assumption	11
1.2.3 Secondary Data	11
1.2.4 Primary Data	11
1.2.5 Data Filtration and Model Design	12
1.2.6 Market Size/Share Estimation	13
1.2.7 Research Limitations	14
1.3 Executive Summary	15
2 Market Overview and Dynamics	17
2.1 Market Size and Forecast	17
2.1.1 Impact of COVID-19 on World Economy	18
2.1.2 Impact of COVID-19 on the Market	20
2.2 Major Growth Drivers	22
2.3 Market Restraints and Challenges	26
2.4 Emerging Opportunities and Market Trends	29
2.5 Porter’s Fiver Forces Analysis	33
3 Segmentation of Europe Market by Treatment Type	37
3.1 Market Overview by Treatment Type	37
3.2 Medication	39
3.3 Stem Cell Therapy	41
3.4 Other Treatments	42
4 Segmentation of Europe Market by ALS Type	43
4.1 Market Overview by ALS Type	43
4.2 Sporadic ALS	45
4.3 Familial ALS	46
5 Segmentation of Europe Market by Distribution Channel	47
5.1 Market Overview by Distribution Channel	47
5.2 Hospital Pharmacies	49
5.3 Retail Pharmacies	50
5.4 Online Pharmacies	51
5.5 Other Distribution Channels	52
6 European Market 2020-2027 by Country	53
6.1 Overview of European Market	53
6.2 UK	56
6.3 France	58
6.4 Germany	60
6.5 Spain	62
6.6 Italy	64
6.7 Russia	66
6.8 Rest of European Market	68
7 Competitive Landscape	70
7.1 Overview of Key Vendors	70
7.2 New Product Launch, Partnership, Investment, and M&A	73
7.3 Company Profiles	74
AB Science SA	74
Amylyx Pharmaceuticals Inc.	76
Biogen Inc.	77
Biohaven Pharmaceutical Holding Co., Ltd.	78
BrainStorm Cell Limited	79
Corestem, Inc.	80
F.Hoffmann-La Roche AG	81
Ionis Pharmaceuticals, Inc.	82
Mitsubishi Tanabe Pharma Corporation	83
Otsuka Pharmaceutical Co., Ltd.	84
Sun Pharmaceutical Industries Ltd.	85
RELATED REPORTS	86
?
List Of Tables

Table 1.  Snapshot of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Balanced Perspective, 2020-2027	16
Table 2. Growth Rate of World GDP, 2020-2022	19
Table 3.  Main Product Trends and Market Opportunities in Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market	29
Table 4. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	37
Table 5. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication by Type, 2017-2027, $ mn	40
Table 6. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	43
Table 7. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	47
Table 8. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn	55
Table 9. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	57
Table 10. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	57
Table 11. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	57
Table 12. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	59
Table 13. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	59
Table 14. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	59
Table 15. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	61
Table 16. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	61
Table 17. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	61
Table 18. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	63
Table 19. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	63
Table 20. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	63
Table 21. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	65
Table 22. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	65
Table 23. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	65
Table 24. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn	67
Table 25. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn	67
Table 26. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn	67
Table 27. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe by Country, 2017-2027, $ mn	69
Table 28. AB Science SA: Company Snapshot	74
Table 29. AB Science SA: Business Segmentation	74
Table 30. AB Science SA: Product Portfolio	75
Table 31. AB Science SA: Revenue, 2017-2019, $ mn	75
List Of Figures

Figure 1. Research Method Flow Chart	10
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	13
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027	15
Figure 4. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn	17
Figure 5. Impact of COVID-19 on Business	20
Figure 6. Primary Drivers and Impact Factors of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market	22
Figure 7.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	25
Figure 8. Primary Restraints and Impact Factors of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market	26
Figure 9. Investment Opportunity Analysis	30
Figure 10. Porter’s Fiver Forces Analysis of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market	33
Figure 11. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2020-2027, % of Revenue	37
Figure 12. Contribution to Europe 2021-2027 Cumulative Revenue by Treatment Type, Value ($ mn) and Share (%)	38
Figure 13. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication, 2017-2027, $ mn	39
Figure 14. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Stem Cell Therapy, 2017-2027, $ mn	41
Figure 15. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Treatments, 2017-2027, $ mn	42
Figure 16. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2020-2027, % of Revenue	43
Figure 17. Contribution to Europe 2021-2027 Cumulative Revenue by ALS Type, Value ($ mn) and Share (%)	44
Figure 18. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Sporadic ALS, 2017-2027, $ mn	45
Figure 19. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Familial ALS, 2017-2027, $ mn	46
Figure 20. Breakdown of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2020-2027, % of Revenue	48
Figure 21. Contribution to Europe 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%)	48
Figure 22. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Hospital Pharmacies, 2017-2027, $ mn	49
Figure 23. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Retail Pharmacies, 2017-2027, $ mn	50
Figure 24. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Online Pharmacies, 2017-2027, $ mn	51
Figure 25. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Distribution Channels, 2017-2027, $ mn	52
Figure 26. Breakdown of European Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue	54
Figure 27. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%)	55
Figure 28.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in UK, 2017-2027, $ mn	56
Figure 29.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in France, 2017-2027, $ mn	58
Figure 30.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Germany, 2017-2027, $ mn	60
Figure 31.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Spain, 2017-2027, $ mn	62
Figure 32.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Italy, 2017-2027, $ mn	64
Figure 33.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Russia, 2017-2027, $ mn	66
Figure 34.  Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe, 2017-2027, $ mn	68
Figure 35. Growth Stage of Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Industry over the Forecast Period	70
Key Players (this may not be a complete list and extra companies can be added upon request): 
AB Science SA
Amylyx Pharmaceuticals Inc.
Biogen Inc.
Biohaven Pharmaceutical Holding Co., Ltd.
BrainStorm Cell Limited
Corestem, Inc.
F.Hoffmann-La Roche AG
Ionis Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
 (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)